SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 384,202.26 |
Enterprise Value ($M) | 392,361.26 |
Book Value ($M) | 68,774.00 |
Book Value / Share | 28.58 |
Price / Book | 5.59 |
NCAV ($M) | -44,944.00 |
NCAV / Share | -18.67 |
Price / NCAV | -8.55 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | 0.39 |
Return on Assets (ROA) | 0.21 |
Return on Equity (ROE) | 0.57 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 0.94 |
Current Ratio | 1.17 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 57,002.00 |
Assets | 171,966.00 |
Liabilities | 101,946.00 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 85,159.00 |
Operating Income | 22,009.00 |
Net Income | 35,153.00 |
Earnings Per Share Diluted | n/a |
Earnings Per Share Basic | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | 22,791.00 |
Cash from Investing | 878.00 |
Cash from Financing | -15,825.00 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G/A | Vanguard Group Inc | 9.53 | -7.07 | |
13G/A | State Street Corp | 5.52 | -6.64 | |
13G/A | BlackRock Inc. | 7.70 | -6.28 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
1,263,032 | 5,830,347 | 21.66 | |
1,516,610 | 7,887,796 | 19.23 | |
1,065,522 | 5,508,505 | 19.34 | |
943,775 | 4,200,838 | 22.47 | |
877,617 | 3,949,626 | 22.22 | |
(click for more detail) |
Similar Companies | |
---|---|
EBS – Emergent BioSolutions Inc. | ELAN – Elanco Animal Health Incorporated |
HYAC – Haymaker Acquisition Corp. 4 | LLY – Eli Lilly and Company |
MRK – Merck & Co., Inc. |